- Latest available (Revised)
- Original (As adopted by EU)
Commission Delegated Regulation (EU) 2020/1182Show full title
Commission Delegated Regulation (EU) 2020/1182 of 19 May 2020 amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)
You are here:
What Version
Advanced Features
- Show Geographical Extent(e.g. England, Wales, Scotland and Northern Ireland)
- Show Timeline of Changes
More Resources
Legislation originating from the EU
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
This item of legislation originated from the EU
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Changes over time for: ANNEX
Changes to legislation:
This version of this Regulation was derived from EUR-Lex on IP completion day (31 December 2020 11:00 p.m.). It has not been amended by the UK since then. Find out more about legislation originating from the EU as published on legislation.gov.uk.
Changes to Legislation
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
ANNEXU.K.
In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:
(1)
the following entries are inserted:
| Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATE | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | ||||||
| ‘007-030-00-3 | nitric acid …% [C ≤ 70 %] | 231-714-2 | 7697-37-2. | Ox. Liq. 3 Acute Tox. 3 Skin Corr. 1A | H272 H331 H314 | GHS03 GHS06 GHS05 Dgr | H272 H331 H314 | EUH071 | Ox. Liq. 3; H272: C ≥ 65 % inhalation: ATE = 2,65 mg/L (vapours) Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % | B’ |
| ‘014-048-00-5 | silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1) | 206-991-8 | 409-21-2 308076-74-6 | Carc. 1B | H350i | GHS08 Dgr | H350i’ | |||
| ‘014-049-00-0 | trimethoxyvinylsilane; trimethoxy(vinyl)silane | 220-449-8 | 2768-02-7 | Skin Sens. 1B | H317 | GHS07 Wng | H317’ | |||
| ‘014-050-00-6 | tris(2-methoxyethoxy)vinylsilane; 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane | 213-934-0 | 1067-53-4 | Repr. 1B | H360FD | GHS08 Dgr | H360FD’ | |||
| ‘016-098-00-3 | dimethyl disulphide | 210-871-0 | 624-92-0 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H400 H410 | GHS02 GHS06 GHS08 GHS09 Dgr | H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H410 | inhalation: ATE = 5 mg/L (vapours) oral: ATE = 190 mg/kg bw M = 1 M = 10’ | ||
| ‘029-024-00-X | granulated copper; [particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm] | 231-159-6 | 7440-50-8 | Aquatic Chronic 2 | H411 | GHS09 | H411’ | |||
| ‘029-025-00-5 | bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O’)copper; bis(N-cyclohexyl-diazenium-dioxy)-copper; [Cu-HDO] | 239-703-4 | 312600-89-8 15627-09-5 | Flam. Sol. 1 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H228 H302 H373 (liver) H318 H400 H410 | GHS02 GHS07 GHS08 GHS05 GHS09 Dgr | H228 H302 H373(liver) H318 H410 | oral: ATE = 360 mg/kg bw M = 1 M = 1’ | ||
| ‘050-031-00-9 | dioctyltin dilaurate; [1] stannane, dioctyl-, bis(coco acyloxy) derivs. [2] | 222-883-3 [1] 293-901-5 [2] | 3648-18-8 [1] 91648-39-4 [2] | Repr. 1B STOT RE 1 | H360D H372 (immune system) | GHS08 Dgr | H360D H372 (immune system)’ | |||
| ‘601-092-00-0 | dibenzo[def,p]chrysene; dibenzo[a,l]pyrene | 205-886-4 | 191-30-0 | Carc. 1B Muta. 2 | H350 H341 | GHS08 Dgr | H350 H341 | Carc. 1B; H350: C ≥ 0,001 %’ | ||
| ‘603-237-00-3 | ipconazole (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol | - | 125225-28-7 115850-69-6 115937-89-8 | Repr. 1B Acute Tox. 4 STOT RE 2 Aquatic Chronic 1 | H360D H302 H373 (eyes, skin, liver) H410 | GHS08 GHS07 GHS09 Dgr | H360D H302 H373 (eyes, skin, liver) H410 | oral: ATE = 500 mg/kg bw M = 100’ | ||
| ‘603-238-00-9 | bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme | 205-594-7 | 143-24-8 | Repr. 1B | H360FD | GHS08 Dgr | H360FD’ | |||
| ‘603-239-00-4 | paclobutrazol (ISO); (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol | - | 76738-62-0 | Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H332 H302 H319 H400 H410 | GHS08 GHS07 GHS09 Wng | H361d H332 H302 H319 H410 | inhalation: ATE = 3,13 mg/L (dusts or mists) oral: ATE = 490 mg/kg bw M = 10 M = 10’ | ||
| ‘603-240-00-X | 2,2-bis(bromomethyl)propane-1,3-diol | 221-967-7 | 3296-90-0 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Dgr | H350 H340’ | |||
| ‘603-241-00-5 | geraniol; (2E)-3,7-dimethylocta-2,6-dien-1-ol | 203-377-1 | 106-24-1 | Skin Sens. 1 | H317 | GHS07 Wng | H317’ | |||
| ‘605-041-00-3 | 2-(4-tert-butylbenzyl)propionaldehyde | 201-289-8 | 80-54-6 | Repr. 1B | H360Fd | GHS08 Dgr | H360Fd’ | |||
| ‘607-738-00-8 | MCPA-thioethyl (ISO); S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate | 246-831-4 | 25319-90-8 | Acute Tox. 4 STOT RE. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 (liver) H400 H410 | GHS07 GHS08 GHS09 Wng | H302 H373 (liver) H410 | oral: ATE = 450 mg/kg bw M = 10 M = 10’ | ||
| ‘607-740-00-9 | diisooctyl phthalate | 248-523-5 | 27554-26-3 | Repr. 1B | H360FD | GHS08 Dgr | H360FD’ | |||
| ‘607-741-00-4 | 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one; flupyradifurone | - | 951659-40-8 | Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 (muscle) H400 H410 | GHS07 GHS08 GHS09 Wng | H302 H373 (muscle) H410 | oral: ATE = 500 mg/kg bw M = 10 M = 10’ | ||
| ‘607-742-00-X | thiencarbazone-methyl (ISO); methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate | - | 317815-83-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1000 M = 1000’ | ||
| ‘607-743-00-5 | L-(+)-lactic acid; (2S)-2-hydroxypropanoic acid | 201-196-2 | 79-33-4 | Skin Corr. 1C Eye Dam. 1 | H314 H318 | GHS05 Dgr | H314 | EUH071’ | ||
| ‘607-744-00-0 | 2-methoxyethyl acrylate | 221-499-3 | 3121-61-7 | Flam. Liq. 3 Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1 | H226 H341 H360FD H331 H302 H314 H318 H317 | GHS02 GHS05 GHS06 GHS08 Dgr | H226 H341 H360FD H331 H302 H314 H317 | EUH071 | inhalation: ATE = 2,7 mg/L (vapours) oral: ATE = 404 mg/kg bw’ | |
| ‘607-745-00-6 | glyoxylic acid …% | 206-058-5 | 298-12-4 | Eye Dam. 1 Skin Sens. 1B | H318 H317 | GHS05 GHS07 Dgr | H318 H317 | B’ | ||
| ‘607-746-00-1 | sodium N-(hydroxymethyl)glycinate; [formaldehyde released from sodium N-(hydroxymethyl)glycinate] | 274-357-8 | 70161-44-3 | Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 | H350 H341 H332 H302 H335 H315 H319 H317 | GHS08 GHS07 Dgr | H350 H341 H332 H302 H335 H315 H319 H317 | inhalation: ATE = 3 mg/L (dusts or mists) oral: ATE = 1100 mg/kg bw | 8 9’ | |
| ‘611-181-00-6 | potassium (oxido-NNO-azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO] | - | 66603-10-9 | Flam. Sol. 1 Acute Tox. 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H228 H301 H373 (liver) H315 H318 H411 | GHS02 GHS06 GHS08 GHS05 GHS09 Dgr | H228 H301 H373 (liver) H315 H318 H411 | oral: ATE = 136 mg/kg bw’ | ||
| ‘612-294-00-3 | mecetronium etilsulfate; N-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate; mecetronium ethyl sulphate; [MES] | 221-106-5 | 3006-10-8 | Skin Corr. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H318 H400 H410 | GHS05 GHS09 Dgr | H314 H410 | EUH071 | M = 100 M = 1000’ | |
| ‘613-331-00-6 | (2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole | - | 1417782-03-6 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 1 M = 1’ | ||
| ‘613-332-00-1 | oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone | - | 1003318-67-9 | Aquatic Chronic 1 | H410 | GHS09 Wng | H410 | M = 1’ | ||
| ‘613-333-00-7 | pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc | 236-671-3 | 13463-41-7 | Repr. 1B Acute Tox. 2 Acute Tox. 3 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H330 H301 H372 H318 H400 H410 | GHS08 GHS06 GHS05 GHS09 Dgr | H360D H330 H301 H372 H318 H410 | inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 221 mg/kg bw M = 1000 M = 10’ | ||
| ‘613-334-00-2 | flurochloridone (ISO); 3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one | 262-661-3 | 61213-25-0 | Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360FD H302 H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H360FD H302 H317 H410 | oral: ATE = 500 mg/kg bw M = 100 M = 100’ | ||
| ‘613-335-00-8 | 4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT] | 264-843-8 | 64359-81-5 | Acute Tox. 2 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H302 H314 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H302 H314 H317 H410 | EUH071 | inhalation: ATE = 0,16 mg/L (dusts or mists) oral: ATE = 567 mg/kg bw Skin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100’ | |
| ‘613-336-00-3 | 2-methyl-1,2-benzothiazol-3(2H)-one; [MBIT] | - | 2527-66-4 | Acute Tox. 4 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2 | H312 H301 H314 H318 H317 H400 H411 | GHS06 GHS05 GHS09 Dgr | H312 H301 H314 H317 H410 | EUH071 | dermal: ATE = 1100 mg/kg bw oral: ATE = 175 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1’ | |
| ‘616-228-00-4 | 3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad | - | 907204-31-3 | Lact. Aquatic Acute 1 Aquatic Chronic 1 | H362 H400 H410 | GHS09 Wng | H362 H410 | M = 1 M = 1’ | ||
| ‘616-230-00-5 | N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA] | 213-103-2 | 924-42-5 | Carc. 1B Muta. 1B STOT RE 1 | H350 H340 H372 (peripheral nervous system) | GHS08 Dgr | H350 H340 H372 (peripheral nervous system)’ | |||
| ‘616-231-00-0 | 5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2'-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen | - | 494793-67-8 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | M = 1 M = 1’ | ||
| ‘616-232-00-6 | iprovalicarb (ISO); isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate | - | 140923-17-7 | Carc. 2 | H351 | GHS08 Wng | H351’ | |||
| ‘616-233-00-1 | silthiofam (ISO); N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide | - | 175217-20-6 | STOT RE 2 Aquatic Chronic 2 | H373 H411 | GHS08 GHS09 Wng | H373 H411’ | |||
| ‘650-057-00-6 | Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide] | 283-644-7 | 84696-25-3 | Aquatic Chronic 3 | H412 | H412’ | ||||
(2)
the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively:
| Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATE | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | ||||||
| ‘007-004-00-1 | nitric acid …% [C > 70 %] | 231-714-2 | 7697-37-2 | Ox. Liq. 2 Acute Tox. 1 Skin Corr. 1A | H272 H330 H314 | GHS03 GHS06 GHS05 Dgr | H272 H330 H314 | EUH071 | Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 70 % ≤ C < 99 % | B’ |
| ‘014-018-00-1 | octamethylcyclotetrasiloxane; [D4] | 209-136-7 | 556-67-2 | Repr. 2 Aquatic Chronic 1 | H361f *** H410 | GHS08 GHS09 Wng | H361f *** H410 | M = 10’ | ||
| ‘015-134-00-5 | pirimiphos-methyl (ISO); O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate | 249-528-5 | 29232-93-7 | Acute Tox. 4 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H372 (nervous system) H400 H410 | GHS07 GHS08 GHS09 Dgr | H302 H372 (nervous system) H410 | oral: ATE = 1414 mg/kg bw M = 1000 M = 1000’ | ||
| ‘015-181-00-1 | phosphine | 232-260-8 | 7803-51-2 | Flam. Gas 1 Press. Gas Acute Tox. 1 Skin Corr. 1B Aquatic Acute 1 | H220 H330 H314 H400 | GHS02 GHS04 GHS06 GHS05 GHS09 Dgr | H220 H330 H314 H400 | inhalation: ATE = 10 ppmV (gases) | U’ | |
| ‘050-021-00-4 | dichlorodioctylstannane | 222-583-2 | 3542-36-7 | Repr. 1B Acute Tox. 2 STOT RE 1 Aquatic Chronic 3 | H360D H330 H372 ** H412 | GHS08 GHS06 Dgr | H360D H330 H372 ** H412 | Repr. 1B; H360 D: C ≥ 0,03 % inhalation: ATE = 0,098 mg/L (dusts or mists)’ | ||
| ‘050-027-00-7 | 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE] | 239-622-4 | 15571-58-1 | Repr. 1B STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H372 (immune system) H400 H410 | GHS08 GHS09 Dgr | H360D H372 (immune system) H410’ | |||
| ‘082-013-00-1 | lead powder; [particle diameter < 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 | H360FD H362 H400 H410 | GHS08 GHS09 Dgr | H360FD H362 H410 | Repr. 1A; H360D: C ≥ 0,03 % M = 1 M = 10’ | ||
| ‘603-014-00-0 | 2-butoxyethanol; ethylene glycol monobutyl ether | 203-905-0 | 111-76-2 | Acute Tox. 4* Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 | H332 H302 H315 H319 | GHS07 Wng | H332 H302 H315 H319 | oral: ATE = 1200 mg/kg bw’ | ||
| ‘603-065-00-9 | m-bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether | 202-987-5 | 101-90-6 | Carc. 1B Muta. 2 Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H350 H341 H311 H302 H315 H319 H317 H412 | GHS08 GHS06 Dgr | H350 H341 H311 H302 H315 H319 H317 H412 | dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw’ | ||
| ‘607-177-00-9 | tribenuron-methyl (ISO); methyl 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate | 401-190-1 | 101200-48-0 | STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H373 H317 H410 | M = 100 M = 100’ | ||
| ‘607-256-00-8 | azoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate | - | 131860-33-8 | Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 | H331 H400 H410 | GHS06 GHS09 Dgr | H331 H410 | inhalation: ATE = 0,7 mg/L (dusts or mists) M = 10 M = 10’ | ||
| ‘607-314-00-2 | ethofumesate (ISO); (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate | 247-525-3 | 26225-79-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1’ | ||
| ‘609-041-00-4 | 2,4-dinitrophenol | 200-087-7 | 51-28-5 | Acute Tox. 3 * Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Acute 1 | H331 H311 H300 H372 H400 | GHS06 GHS08 GHS09 Dgr | H331 H311 H300 H372 H400 | dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw’ | ||
| ‘609-064-00-X | mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione | - | 104206-82-8 | Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H373 (eyes, nervous system) H400 H410 | GHS08 GHS09 Wng | H361d H373 (eyes, nervous system) H410 | M = 10 M = 10’ | ||
| ‘613-112-00-5 | octhilinone (ISO); 2-octyl-2H-isothiazol-3-one; [OIT] | 247-761-7 | 26530-20-1 | Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H311 H301 H314 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H311 H301 H314 H317 H410 | EUH071 | inhalation: ATE = 0,27 mg/L (dusts or mists) dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100’ | |
| ‘613-115-00-1 | hymexazol (ISO); 3-hydroxy-5-methylisoxazole | 233-000-6 | 10004-44-1 | Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H361d H302 H318 H317 H411 | GHS08 GHS07 GHS05 GHS09 Dgr | H361d H302 H318 H317 H411 | oral: ATE = 1600 mg/kg bw’ | ||
| ‘613-125-00-6 | hexythiazox (ISO); trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide | - | 78587-05-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1’ | ||
| ‘613-202-00-4 | pymetrozine (ISO); (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one | - | 123312-89-0 | Carc. 2 Repr. 2 Aquatic Chronic 1 | H351 H361fd H410 | GHS08 GHS09 Wng | H351 H361fd H410 | M = 1’ | ||
| ‘613-259-00-5 | imiprothrin (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate | 428-790-6 | 72963-72-5 | Carc. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H332 H302 H371 (nervous system; oral, inhalation) H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H332 H302 H371 (nervous system; oral, inhalation) H410 | inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 550 mg/kg bw M = 10 M = 10’ | ||
| ‘616-014-00-0 | butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime | 202-496-6 | 96-29-7 | Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 STOT SE 1 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317 | GHS08 GHS06 GHS05 Dgr | H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317 | dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw’ | ||
| ‘617-006-00-X | bis(α,α-dimethylbenzyl) peroxide | 201-279-3 | 80-43-3 | Org. Perox. F Repr. 1B Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 2 | H242 H360D H315 H319 H411 | GHS02 GHS08 GHS07 GHS09 Dgr | H242 H360D H315 H319 H411’ | |||
(3)
the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.
Options/Help
Print Options
PrintThe Whole Regulation
PrintThis Annex only
Legislation is available in different versions:
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
See additional information alongside the content
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Opening Options
Different options to open legislation in order to view more content on screen at once
More Resources
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the EU Official Journal
- lists of changes made by and/or affecting this legislation item
- all formats of all associated documents
- correction slips
- links to related legislation and further information resources
Timeline of Changes
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
More Resources
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the print copy
- correction slips
Click 'View More' or select 'More Resources' tab for additional information including:
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- links to related legislation and further information resources
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.